Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: ace-031
Validated Laboratory Standard
Preclinical & Clinical Literature MonographSingle Peptide
Ace-031
Revision 1 · Lyophilized Solid Powder
Soluble Activin Receptor Type IIB Fusion Protein · Decoy Receptor Standard. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
Ace-031
Soluble Activin Receptor Type IIB Fusion Protein · Decoy Receptor Standard. Formulated for in-vitro research and laboratory analytical validation.
≥99.0% (HPLC-grade)Growth Hormone Axis
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~10 to 15 DaysTypical protocol duration: 8 to 16 Weeks; Washout: 4 Weeks between research cohorts
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationWhat it is: Ace-031 is an engineered soluble decoy receptor consisting of the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) fused to the Fc portion of human IgG1.
How it works: By binding tightly to circulating myostatin, GDF-11, and activins, Ace-031 prevents these inhibitory ligands from interacting with cellular cell-surface ActRIIB receptors, driving pronounced lean muscle mass gains.
Why researchers study it: Researched in Phase 1/2 human clinical trials for Duchenne muscular dystrophy and ambulatory muscle preservation.
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
ActRIIB Receptor Decoy Fusion: Soluble receptor binding both myostatin (GDF-8) and activin-A/B with sub-nanomolar affinity.
✓
Unrivaled Muscle Mass Accumulation: Produced the highest rate of muscle hypertrophy recorded in clinical Phase 1 cohorts.
✓
Bone Mineral Density Elevation: Concurrent activin inhibition drives increased trabecular bone volume and osteoblast activity.
✓
Adipose Browning & Lipolysis: Increases energy expenditure and promotes brown fat thermogenesis.
Physicochemical Specifications & Analytical Verification
≥99.0% (HPLC-grade)Primary Sequence / Chemical Formula
Soluble Activin Receptor Type IIB (ActRIIB-Fc Fusion)
Diluent Ratio
1 mL per 1 mg (1 mg/mL)
Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
Lyophilized Storage
-20°C in dry desiccated container (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~10 to 15 Days
Typical protocol duration: 8 to 16 Weeks; Washout: 4 Weeks between research cohorts
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (2 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake2 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent2.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution1.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 10.0 mcg (0.01 mL)| Standard Compound Mass | 2 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 1.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 10.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— Ace-031
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)
1. Compound Mass1 mg
mg
Vials:
2. Diluent Volume1.0 mL
mL
Quick:
3. Target Assay Dose100.0 Units
Dissolution Vial
1mg / 1mL
Syringe: 100 U (1.0 mL Workhorse)
100.0 Units (1.000 mL)
0 U100 U
Selected Dose
1 mg
1000 µg active mass
Injection Volume
1.000 mL
1000 µL draw
U-100 Syringe Mark
100.0 Units
Barrel Graduation
Single Vial Yield
~1.0 Doses
1 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: Ace-031•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (1mg / 1.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Day 1) | 500 mcg | 50.0 Units(0.50 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Day 15 & Day 29) | 1 mg | 100.0 Units(1.00 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Day 43+) | 1 mg | 100.0 Units(1.00 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 1mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 12.0 mg
Active Vials (1mg):13 vials
Sterile Syringes:12 U-100
BAC Water (10mL):2 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 24.0 mg
Active Vials (1mg):26 vials
Sterile Syringes:24 U-100
BAC Water (10mL):3 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 100.0 Units (1.00 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 500 mcg | 0.50 mL | 50 Units 50.0 units (0.50 mL) on U-100 syringe |
| 1000 mcg | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
| 1000 mcg | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
0.3 mL or 0.5 mL U-100 Micro-Barrel
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent transfer
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle: 31G Ultra-Fine (0.25 mm)
Active Compound Mass1 mgSingle Lyophilized Vial
Diluent Volume Added1.0 mLBacteriostatic Water USP
Resulting Concentration1.00 mg/mLHomogenized Solution
Vial Yield~1.0 DosesPer Single Reconstituted Vial
Target Analytical Dose1 mg1000 µg active mass
Volumetric Draw1.000 mL (1000 µL)Calibrated Liquid Draw
U-100 Syringe Graduation100.0 UnitsPlunger Barrel Mark
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 100.0 units (1.00 mL)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 500 mcg | 0.5 mL (500 µL) | 50 Units | 50.0 units (0.50 mL) on U-100 syringe |
| 1000 mcg | 1 mL (1000 µL) | 100 Units | 100.0 units (1.00 mL) on U-100 syringe |
| 1000 mcg | 1 mL (1000 µL) | 100 Units | 100.0 units (1.00 mL) on U-100 syringe |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
50 U-100 Units (0.5 mL)
Mass @ 1.0 mg/mL:500 mcg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:1 mL Barrel Standard
✓ Exact Tick Mark Alignment (50 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 50.0% of barrel
Tick Increment
2 Unit (20 µL)
Volumetric step
Low-Dead-Space (LDS)
<2.1 µL (0.42%)
Integrated needle waste
Measurement Error
±4.5%
ISO 8537 tolerance
Needle Configuration
29G (0.33mm)
1/2" (12.7mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (Ace-031)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 2.1 µL
Wastage per Titration:0.42% of dose
84-Day Cumulative Loss:0.176 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:9.9% of dose
84-Day Cumulative Loss:4.62 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 50 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units) | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✕ Exceeded by 20 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 50 units |
| 1 mL (100 Units)BEST FIT | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 50 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for Ace-031.
Active Compound
84.00 mg
Across 12 weeks (84 doses)
Vials Required
46 × 2mg
Includes 8% dead-space buffer
Bacteriostatic Water
4 × 30 mL Bottles
92.0 mL total diluent
Sterile Syringes
134 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
268 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 46 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #2(0mg rem) | 7.0 mg / 84.0 mg |
| Week 2 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #3(0mg rem) | 14.0 mg / 84.0 mg |
| Week 3 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #4(0mg rem) | 21.0 mg / 84.0 mg |
| Week 4 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #5(0mg rem) | 28.0 mg / 84.0 mg |
| Week 5 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #6(0mg rem) | 35.0 mg / 84.0 mg |
| Week 6 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #7(0mg rem) | 42.0 mg / 84.0 mg |
| Week 7 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #8(0mg rem) | 49.0 mg / 84.0 mg |
| Week 8 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #9(0mg rem) | 56.0 mg / 84.0 mg |
| Week 9 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #10(0mg rem) | 63.0 mg / 84.0 mg |
| Week 10 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #11(0mg rem) | 70.0 mg / 84.0 mg |
| Week 11 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #12(0mg rem) | 77.0 mg / 84.0 mg |
| Week 12 | Stage 3: Cohort Evaluation (Day 43+) | 1.0 mg(7x/wk) | 100 Units(1.00 mL) | Vial #13(0mg rem) | 84.0 mg / 84.0 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: 8 to 16 Weeks · Washout: 4 Weeks between research cohorts
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Day 1Starting Baseline | 500 mcg | Day 1 | Stage 1: Initial Calibration: Receptor saturation baseline (50.0 units (0.50 mL) at 1.0 mg/mL) |
| Day 15 & Day 29 | 1 mg | Every 14 Days | Stage 2: Target Maintenance: Sustained ligand blockade (100.0 units (1.00 mL)) |
| Day 43+ | 1 mg | Every 14 Days | Stage 3: Cohort Evaluation: Lean tissue mass accretion (100.0 units (1.00 mL)) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓ActRIIB Receptor Decoy Fusion: Soluble receptor binding both myostatin (GDF-8) and activin-A/B with sub-nanomolar affinity.
✓Unrivaled Muscle Mass Accumulation: Produced the highest rate of muscle hypertrophy recorded in clinical Phase 1 cohorts.
✓Bone Mineral Density Elevation: Concurrent activin inhibition drives increased trabecular bone volume and osteoblast activity.
✓Adipose Browning & Lipolysis: Increases energy expenditure and promotes brown fat thermogenesis.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes!Vascular Fragility at High Doses: Clinical trials observed telangiectasias and minor nosebleeds due to BMP9/10 cross-inhibition.
!Dose-Limiting Threshold: Research protocols must adhere strictly to conservative micro-dosing (0.1–0.3 mg/kg).
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
-20°C in dry desiccated container (24 months)
Reconstituted Solution
2°C–8°C refrigerated; use within 28 days
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for Ace-031
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at -20°C in dry desiccated container (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (1 References)
Peer-Reviewed IndexPMID: 23144106
Verified scientific reference.
Frequently Asked Questions
How should Ace-031 (ActRIIB-Fc) be reconstituted?
Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
What is the estimated laboratory half-life of Ace-031 (ActRIIB-Fc)?
Ace-031 (ActRIIB-Fc) displays an estimated half-life of ~10 to 15 Days. Typical study protocols run for 8 to 16 Weeks followed by a washout period of 4 Weeks between research cohorts.
Pharmacological Profile and Mechanism
What it is: Ace-031 is an engineered soluble decoy receptor consisting of the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) fused to the Fc portion of human IgG1.
How it works: By binding tightly to circulating myostatin, GDF-11, and activins, Ace-031 prevents these inhibitory ligands from interacting with cellular cell-surface ActRIIB receptors, driving pronounced lean muscle mass gains.
Why researchers study it: Researched in Phase 1/2 human clinical trials for Duchenne muscular dystrophy and ambulatory muscle preservation.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 1 mL of Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.
Storage and Temperature Stability
Lyophilized powder: -20°C in dry desiccated container (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 28 days. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 1160514-60-2
PubChem CID: 137088485
Formula/Sequence: Soluble Activin Receptor Type IIB (ActRIIB-Fc Fusion)
Molecular Weight: 110000 g/mol
In-Vitro Concentration & Assay Schedule
• Stage 1: Initial Calibration (Day 1): Target Assay Dose: 500 mcg | Cadence: Day 1
Assay Focus: Receptor saturation baseline
Volumetric Calibration: 50.0 units (0.50 mL) at 1.0 mg/mL
• Stage 2: Target Maintenance (Day 15 & Day 29): Target Assay Dose: 1000 mcg | Cadence: Every 14 Days
Assay Focus: Sustained ligand blockade
Volumetric Calibration: 100.0 units (1.00 mL)
• Stage 3: Cohort Evaluation (Day 43+): Target Assay Dose: 1000 mcg | Cadence: Every 14 Days
Assay Focus: Lean tissue mass accretion
Volumetric Calibration: 100.0 units (1.00 mL)
Typical Study Duration: 8 to 16 Weeks
Receptor Washout Window: 4 Weeks between research cohorts
All materials are synthesized strictly for controlled in-vitro and laboratory research use only. Not for human, veterinary, therapeutic, or clinical administration.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
Ace-031
Standard Lyophilized Monograph
Doc ID: PSL-SOP-ACE031-REV1Rev: 1Category: Growth Hormone AxisDate: September 28, 2026
QR CODE
Verify Lot COApepstacklabs.com/sitemap.xml/research-protocols/ace-031Pharmacological Profile & Monograph
Soluble Activin Receptor Type IIB Fusion Protein · Decoy Receptor Standard. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:Ace-031
CAS Registry Number:1160514-60-2
PubChem CID:137088485
Molecular Weight:110000 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:Soluble Activin Receptor Type IIB (ActRIIB-Fc Fusion)
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · ACE-031DOC ID: PSL-SOP-ACE031-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 1 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 1.0 mL | 1.00 mg/mL | 1 Unit = 10.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (50 U / 0.5 mL)Target Mark: 50.0 Units (0.500 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 50.0 Units (0.500 mL)50 U (0.5 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 1.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · ACE-031DOC ID: PSL-SOP-ACE031-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 500 mcg | 50.0 Units (0.500 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 750 mcg | 75.0 Units (0.750 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 500 mcg | 50.0 Units (0.500 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 1mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-ACE031-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3